NEBION continuously curates COVID-19 related gene expression studies and integrates them into GENEVESTIGATOR®. Using our unique tools, scientists can characterize this disease at the molecular level from multiple perspectives and compare results with thousands of other public datasets.
The following table describes high-quality human and mouse RNA-Seq and microarray studies that have been deeply curated and integrated into GENEVESTIGATOR®
for research on COVID-19. Included in this collection are primarily studies investigating molecular changes associated with SARS-CoV-2 infections, as well as secondary studies investigating experimental COVID-19 treatments (repurposed) in the context of their original use.
To learn more about GENEVESTIGATOR® and how you can analyze and visualize this data, visit the GENEVESTIGATOR® website.
| GENEVESTIGATOR® ID | Repository ID (s) | Study Title | Number of Samples |
|---|---|---|---|
| HS-03448 | GSE100496/ GSE100504/ GSE100509/ GSE65574/ GSE79172/ GSE79218/ GSE79458/ GSE81909/ GSE86528/ GSE86529/ GSE86530 (part of GSE65575) | Modeling Host Responses to Understand Severe Human Virus Infections | 542 |
| HS-03495 | GSE150392 | RNA-Seq of Human iPSC-cardiomyocytes infected with SARS-CoV-2 | 6 |
| HS-03479 | GSE150316 | Spectrum of Viral Load and Host Response Seen in Autopsies of SARS-CoV-2 Infected Lungs | 32 |
| HS-03524 | GSE151161 | Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19 | 76 |
| HS-03482 | GSE149273 | RV infections in asthmatics increase ACE2 expression and stimulate cytokine pathways implicated in COVID19 | 90 |
| HS-03493 | GSE151803 | Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids | 16 |
| HS-03502 | GSE148729 | Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (total RNA) | 14 |
| HS-03490 | GSE148729 | Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (poly A) | 70 |
| HS-03525 | GSE153970 | Primary Human Airway Epithelial Cultures infected with SARS-CoV-2 | 6 |
| HS-03527 | GSE154613 | Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds | 63 |
| HS-03480 | GSE150819 | Generation of human bronchial organoids for SARS-CoV-2 research. | 18 |
| HS-03481 | GSE149312 | Bulk RNA sequencing of SARS-CoV and SARS-CoV-2 infected human intestinal organoids. | 22 |
| HS-00702 | GSE17400 | Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells against SARS-CoV and DOHV infection. | 27 |
| HS-03427 | GSE47963 (superseries of GSE47960, GSE47961, GSE47962) | SARS-CoV, SARS-dORF6 and SARS-BatSRBD infection of HAE cultures. | 438 |
| HS-03426 | GSE45042 | Cell host-response to infection with novel human coronavirus EMC predict potential antivirals and important differences with SARS-coronavirus | 32 |
| HS-03424 | GSE56677 | Cytokine stimulation systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates. | 32 |
| HS-03423 | GSE37827 | SCL006, icSARS CoV Urbani or icSARS Bat SRBD (spike receptor binding domain from the wild type strain Urbani to allow for infection of human and non-human primate cells) infections of the 2B4 clonal derivative of Calu-3 cells - Time course | 87 |
| HS-03422 | GSE33267 | SCL005: icSARS CoV Urbani or icSARS deltaORF6 infections of the 2B4 clonal derivative of Calu-3 cells - Time course | 99 |
| HS-03420 | GSE147507 | Transcriptional response to SARS-CoV-2 infection | 67 |
| HS-03375 | GSE148817 (part of GSE148818) | Cell-intrinsic differences between human tracheal epithelial cells from children and adults | 6 |
| HS-03244 | GSE78068 | Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study | 209 |
| HS-02837 | GSE25160 | Combination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis | 26 |
| HS-02781 | GSE46293 (Superserie of GSE46280, GSE46282, GSE46283, GSE46292) | Expression data of multiple sclerosis patients receiving Interferon-beta therapy | 24 |
| HS-01798 | GSE56192 (part of GSE56189) | Transcriptomic analysis of the Novel Middle East Respiratory Syndrome Coronavirus (Human, MRC5 cells) | 25 |
| HS-01477 | GSE17183 | Hepatic gene expression before and during interferon and ribavirin combination therapy | 98 |
| HS-01237 | GSE45867 | Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium | 40 |
| HS-00214 | GSE7123 | Gene profiling of responders and non-responders to antiviral therapies peg interferon and ribavirin against hepatitis C | 341 |
| MM-01639 | GSE148829 | SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues | 65 |
| MM-01685 | GSE150847 | Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment | 6 |
| MM-01637 | GSE59185, GSE52920 | Host responses contributing to the attenuation of severe acute respiratory syndrome coronaviruses missing E protein domains / GSE52920 | 18 |
| MM-01636 | GSE131936 | Relative timing of type I interferon response and virus replication determines disease outcome during MERS-CoV infection | 16 |
| MM-01635 | GSE146074 | LY6E blocks coronavirus fusion and confers immune control of viral disease | 36 |
| MM-01632 | GSE49262, GSE49263 | SM012 - SARS MA15 wild type, and SARS deltaORF6 mutant virus infections of C57BL6 mice - A time course | 75 |
| MM-00498 | GSE21583 | Effects of ACE2 on BMPR2 mutation-mediated defects in gene expression | 8 |
| MM-01448 | GSE84709 | Expression data of Brain CD11b+ cells from WT and DP1 knockout mice infected with rJ2.2 | 7 |
| MM-01140 | GSE36016 | Transcriptomic analysis of host response to mouse-adapted SARS virus in wild type, STAT1 -/-, and IFNAR1 -/- mouse genetic backgrounds | 36 |
| MM-01109 | GSE51386 | SM004 - SARS infection of C57BL6, TIMP1 and Serpine1 knock-out mice | 38 |
Table: These human and mouse RNA-Seq and Microarray studies in GENEVESTIGATOR® investigate gene expression changes associated with SARS-CoV-2 and changes associated with experimental treatments of COVID-19.